Literature DB >> 2902695

Reinfusion of secretions from high-output proximal stomas or fistulas.

W Rinsema1, D J Gouma, M F von Meyenfeldt, P B Soeters.   

Abstract

Patients with proximal stomas or high fistulas and defunctionalized intestine who are receiving total parenteral nutrition (TPN) often develop hepatic enzyme abnormalities and hyperbilirubinemia. A technique was developed to collect intestinal secretions from proximal stoma and to reinfuse these secretions into the distal part of the intestine. This technique was applied in eight patients with a disrupted intestinal tract. A significant decrease (p less than 0.05) in elevated serum bilirubin, alkaline phosphatase and gamma-glutamyl transpeptidase levels was observed. Alanine aminotransferase and aspartate aminotransferase levels did not change significantly. The plasma sodium levels, slightly subnormal before reinfusion (131.0 +/- 4.6 millimolar per liter), despite enormous supplementation, normalized during reinfusion (137.0 +/- 4.0 millimolar per liter). TPN was continued during this infusion. This suggests that TPN by itself does not cause intrahepatic cholestasis. Neither could it be explained by an effect of secondary bile acids because these were most likely not produced as bile did not reach the distal defunctionalized intestine. Three possible mechanisms are suggested. Restoration of passage in the distal intestine may diminish bacterial overgrowth, endotoxin production and absorption. Enlargement of the bile acid pool may diminish the susceptibility of the liver to the deleterious effects of endotoxins. We advocate this reinfusion technique to overcome the metabolic disturbances occurring in those patients with high-output stomas or fistulas arising from the proximal parts of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902695

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

Review 1.  A serendipitous voyage in the field of nutrition and metabolism in health and disease: a translational adventure.

Authors:  Peter B Soeters
Journal:  Eur J Clin Nutr       Date:  2020-02-14       Impact factor: 4.016

2.  Reversal of intestinal failure-associated liver disease (IFALD): emphasis on its multifactorial nature.

Authors:  Christian Hvas; Kamelia Kodjabashia; Emma Nixon; Stephen Hayes; Kirstine Farrer; Arun Abraham; Simon Lal
Journal:  Frontline Gastroenterol       Date:  2015-04-09

3.  FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease.

Authors:  Kiran V K Koelfat; Ruben G J Visschers; Caroline M J M Hodin; D Rudi de Waart; Wim G van Gemert; Jack P M Cleutjens; Marion J Gijbels; Ronit Shiri-Sverdlov; Rajeshwar P Mookerjee; Kaatje Lenaerts; Frank G Schaap; Olde Damink Steven W M
Journal:  J Clin Transl Res       Date:  2017-10-15

4.  Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure.

Authors:  Kiran V K Koelfat; Denis Picot; Xinwei Chang; Ronan Thibault; Frank G Schaap; Steven W M Olde Damink; Mireille Desille-Dugast; Hans M van Eijk; Sander M J van Kuijk; Martin Lenicek; Sabrina Layec; Marie Carsin; Laurence Dussaulx; Eloi Seynhaeve; Florence Trivin; Laurence Lacaze
Journal:  Hepatology       Date:  2021-08-26       Impact factor: 17.425

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.